![Barrie Charles Finnin](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Barrie Charles Finnin
Direttore/Membro del Consiglio presso PolyActiva Pty Ltd.
Posizioni attive di Barrie Charles Finnin
Società | Posizione | Inizio | Fine |
---|---|---|---|
PolyActiva Pty Ltd.
![]() PolyActiva Pty Ltd. BiotechnologyHealth Technology PolyActiva Pty Ltd. develops drug-polymer conjugate technology. Its platform technology is used to make plastic components for medical devices from drugs and manufacture process is novel and provides greater flexibility over the composition of the final material and better product outcomes compared with competitor technologies. The firm has built drug-polymer conjugates from a number of drug candidates with different chemical structures and linkage points, demonstrating the plasticity of the technology and developed a number of functional co-monomers and polymer segments, which modularises the production of the final conjugate. The company was founded in February 2010 and is headquartered in Melbourne, Australia. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Barrie Charles Finnin
Precedenti posizioni note di Barrie Charles Finnin
Società | Posizione | Inizio | Fine |
---|---|---|---|
ACRUX LIMITED | Direttore/Membro del Consiglio | 01/01/1998 | 31/08/2011 |
Fondatore | 01/01/1998 | - | |
Therapeutic Goods Administration | Corporate Officer/Principal | - | - |
Statistiche
Distribuzione geografica
Australia | 4 |
Posizioni
Director/Board Member | 2 |
Founder | 1 |
Corporate Officer/Principal | 1 |
Settori
Health Technology | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
ACRUX LIMITED | Health Technology |
Aziende private | 2 |
---|---|
PolyActiva Pty Ltd.
![]() PolyActiva Pty Ltd. BiotechnologyHealth Technology PolyActiva Pty Ltd. develops drug-polymer conjugate technology. Its platform technology is used to make plastic components for medical devices from drugs and manufacture process is novel and provides greater flexibility over the composition of the final material and better product outcomes compared with competitor technologies. The firm has built drug-polymer conjugates from a number of drug candidates with different chemical structures and linkage points, demonstrating the plasticity of the technology and developed a number of functional co-monomers and polymer segments, which modularises the production of the final conjugate. The company was founded in February 2010 and is headquartered in Melbourne, Australia. | Health Technology |
Therapeutic Goods Administration |